Related Experiment Video

Updated: Mar 17, 2026

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

4.8K

Prognostic value of left ventricular phenotypes by cardiac magnetic resonance in elderly and non-elderly patients

Rungroj Krittayaphong1, Thammarak Songsangjinda2, Kanchalaporn Jirataiporn3

  • 1Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Journal of Geriatric Cardiology : JGC
|March 16, 2026
PubMed

Insights

Left ventricular (LV) phenotypes identified by cardiac magnetic resonance (CMR) predict adverse outcomes in elderly patients with coronary artery disease. This classification aids in risk stratification for better patient management.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Clinical Research

Background:

  • Left ventricular (LV) phenotypes, classified by mass and geometry, can be affected by various conditions.
  • Limited data exists on the prognostic value of LV phenotypes determined by cardiac magnetic resonance (CMR).

Purpose of the Study:

  • To determine the prognostic value of LV phenotypes in elderly and non-elderly patients with known or suspected coronary artery disease.
  • To assess if LV phenotypes identified via CMR can aid in risk stratification.

Main Methods:

  • Retrospective cohort study of 3289 patients undergoing stress or viability CMR.
  • LV phenotypes classified into normal, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy based on LV mass index, end-diastolic volume index, and mass/volume ratio.
  • Primary outcome: composite of death or heart failure, with a median follow-up of 41.4 months.

Main Results:

  • Elderly patients (≥65 years) showed a more pronounced prognostic impact of LV phenotypes.
  • Eccentric hypertrophy indicated the worst prognosis in the elderly (aHR 2.37), followed by concentric hypertrophy (aHR 1.53) and concentric remodeling (aHR 1.14) compared to normal phenotype.
  • Patients with eccentric hypertrophy also exhibited abnormal LV strain and extracellular volume fraction.

Conclusions:

  • LV phenotypes assessed by CMR are independent predictors of adverse clinical outcomes in elderly patients with coronary artery disease.
  • The prognostic value of LV phenotypes was less apparent in non-elderly individuals.
  • LV phenotype assessment using CMR can be a valuable tool for risk stratification in patients with suspected or known coronary artery disease.
Abstract

More Related Videos

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

15.1K
Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.9K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
618
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
387
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
791
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716